|
End-of-day quote
Korea S.E.
2026-08-25
|
5-day change | 1st Jan Change | ||
| 189,600.00 KRW | -2.27% |
|
-3.02% | +9.99% |
| 08-25 | Celltrion Launches Omlyclo 300 Mg Strength In Key European Markets | CI |
| 08-23 | Celltrion Submits Marketing Application for Keytruda Biosimilar in South Korea | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- A068270 Stock
- Consensus Celltrion, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
